[Comparative efficacy of immunomodulation treatment schemes in patients with herpetic prostatitis]

The immune status was studied in 150 patients with herpetic prostatitis before and after therapy. All the patients were divided into three groups: group 1 (n=50) received standard therapy, group 2 (n=50) received standard therapy plus immunocorrection, group 3 (n=50)--standard therapy, immunocorrection and inductor of interferon. Combined treatment in group 3 produced changes in parameters of cellular and humoral immunity associated with regress of herpetic prostatitis manifestations and reduction in the number of relapses.